ClinicalTrials.gg
Active, not recruitingNCT04243499EVICTIONUpdated Sep 4, 2026

First-in-Human Study of ICT01 in Patients With Advanced Cancer

A Phase 1/2 interventional study of IV ICT01 in Solid Tumor, Adult and Hematopoietic/Lymphoid Cancer, sponsored by ImCheck Therapeutics, an Ipsen company. Active, not recruiting at 29 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by ImCheck Therapeutics, an Ipsen company (part of Ipsen) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
293
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 142 studies in Hematologic Neoplasms with a site in France — 49 open to participants now, 58 under way, 5 of them phase 3. Hematologic Neoplasms · France.

Enrollment
21st of 107
293 · median 106
Started
2020
with 8 others
Phase 1/2
17 of 142
6 open now
Primary completion
2027-10
later than 31 of 57 live
Registered
75th of 142
by date

Among the 142 studies in Hematologic Neoplasms with a site in France, this one is the 21st largest by enrollment of the 107 interventional ones that give a count, is one of 9 that started in 2020, is one of 17 in phase 1/2, reaches primary completion later than 31 of the 57 other live ones, and was the 75th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 423 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

49 of the 142 studies in Hematologic Neoplasms with a site in France are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 314 Hematologic Neoplasms studies recruiting now, 210 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in Hematologic Neoplasms with a site in France, or all of them as a file.
02

Study summary

Part 1 will be a dose escalation study of IV ICT01 (a monoclonal antibody targeting BTN3A) as monotherapy in patients with advanced solid or hematologic tumors, followed by a cohort examining the combination of ICT01 plus pembrolizumab (Keytruda). Part 2 will be a cohort expansion into 2 solid tumor indications and one hematologic malignancy for ICT01 monotherapy, and 3 solid tumor indications for the combination of ICT01 plus pembrolizumab.

03

Conditions studied

  • Solid Tumor, Adult
  • Hematopoietic/Lymphoid Cancer

Keywords

  • gamma delta T cells
  • butyrophilin
  • pembrolizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily signed form.
  2. patients with or cytologically confirmed diagnosis of advanced-stage or recurrent cancer, including:

    Group A: bladder, breast, colon, gastric, melanoma, ovarian, prostate and PDAC Group B: hematologic including acute myeloid leukemia, acute lymphocytic leukemia, Diffuse large B cell lymphoma and follicular lymphoma Group C: melanoma, cervical, bladder, gastric, head and neck SCC, and lymphoma (according to the approved package labeling of the ICI) Part 2, Group D: Ovarian cancer (2L/3L) with baseline g9d2 T cells > 20K Part 2, Group E: castrate resistant prostate cancer (2L/3L) with baseline g9d2 T cells > 20K Part 2, Group F: newly diagnosed AML starting venetoclax/azacitidine Part 2, Group G: checkpoint-refractory metastatic melanoma with g9d2 T cells >5K Part 2, Group H: chemotx-refractory or Pt-ineligible urotherlial cancer (bladder) with g9d2 T cells >5K Part 2, Group I: checkpoint-refractory, metastatic HNSCC with g9d2 T cells >5K

  3. (ECOG) performance status ≤ 1
  4. > 3 months as assessed by the Investigator
  5. At least 1 per (RECIST)/ Response Evaluation Criteria in Lymphoma (RECIL) or >5% marrow blasts

Exclusion criteria

Exclusion Criteria:

  1. Any of Vγ9Vδ2 T cell origin
  2. Any anti-tumor-directed drug therapy within 28 days or 5 times the elimination half-life (whichever is shorter) before study treatment (does not apply to patients receiving ICI for the combination arm)
  3. Treatment with drug(s) within 28 days before study treatment
  4. Systemic at a daily dose of > 10 mg of prednisone, > 2 mg of dexamethasone or equivalent, for the last 28 days and need for ongoing treatment.
  5. Patients with rapidly progressing disease defined as advanced/, symptomatic, visceral spread, with a risk of life-threatening complications in the short term (e.g., during Screening Period/ treatment ) that includes patients with massive uncontrolled effusions pleural, pericardial, peritoneal, pulmonary lymphangitis, and over 50% liver involvement
  6. Ongoing immune-related adverse events (irAEs) and/or AEs ≥grade 2 not resolved from previous therapies except vitiligo, stable neuropathy up to grade 2, hair loss, and stable endocrinopathies with replacement hormone therapy.
  7. Within 4 weeks of major surgery
  8. Documented history of active disorders requiring systemic therapy within the last 12 months
  9. Primary or secondary immune deficiency
  10. Active and uncontrolled infections requiring intravenous antibiotic or antiviral treatment
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
293 participants (actual)

Study arms

  • Experimental
    IV ICT01 Monotherapy

    Up to six ICT01 dose levels administered as IV monotherapy every 3 weeks will be tested in Part 1 Dose Escalation and up to 2 dose levels in Part 2 Cohort Expansion

    Biological: IV ICT01

  • Experimental
    IV ICT01 + IV Pembrolizumab

    A range of IV ICT01 doses administered every 3 weeks will be tested in combination with 200 mg pembrolizumab in Part 1 Dose Escalation and up to 2 dose levels of ICT01 plus 200 mg pembrolizumab in Part 2 Cohort Expansion

    Biological: IV ICT01

Interventions

  • BiologicalIV ICT01

    humanized anti-Butyrophilin 3A (BTN3A) monoclonal antibody

This study also gives Pembrolizumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Percentage of participants with TEAES (Part 1)

    Treatment emergent adverse events (TEAEs) with severity according to National Cancer Institute \[NCI\]- Common Terminology Criteria for Adverse Events \[CTCAE\] Version 5.0.

    Time frame: From baseline to at least 6 months

  2. Percentage of participants with TEAES leading to discontinuation of study treatment or treatment modifications (Part 1)

    Treatment emergent adverse events (TEAEs) with severity according to National Cancer Institute \[NCI\]- Common Terminology Criteria for Adverse Events \[CTCAE\] Version 5.0.

    Time frame: From baseline to at least 6 months

  3. Percentage of participants with SAEs (Part 1)

    Serious Adverse Events (SAEs) with severity according to National Cancer Institute \[NCI\]- Common Terminology Criteria for Adverse Events \[CTCAE\] Version 5.0

    Time frame: From baseline to at least 6 months

  4. Percentage of participants with clinically significant change from baseline clinical laboratory abnormalities (Part 1)

    With severity measured according to NCI-CTCAE Version 5.0

    Time frame: From baseline to at least 6 months

  5. Percentage of participants with clinically significant change from baseline vital sign readings (Part 1)

    Vital signs will be assessed by the investigators for clinical significance.

    Time frame: From baseline to at least 6 months

  6. Percentage of participants with clinically significant change from baseline in 12-lead Electrocardiogram (ECG) readings (Part 1)

    12-lead (echocardiogram) ECGs will be assessed by the investigators for clinical significance.

    Time frame: From baseline to at least 6 months

  7. Percentage of participants with clinically significant change from baseline physical examinations (Part 1)

    Physical examinations will be assessed by the investigators for clinical significance.

    Time frame: From baseline to at least 6 months

  8. Duration of Complete Response (DCR) (Part 2)

    DCR according to RECIST Version 1.1 for all groups except Group F (complete response \[CR\] + partial response \[PR\] + stable disease \[SD\]);

    Time frame: From baseline to at least 6 months

Secondary outcomes

  1. Change from Baseline in the Number of Circulating Gamma Delta T Cells

    Flow cytometric counting of circulating gamma delta T cells

    Time frame: 28 days

  2. Cmax following the first dose of ICT01

    PK parameter from serum ICT01 levels

    Time frame: 1 day

  3. AUC following the first dose of ICT01

    PK parameter from serum ICT01 levels

    Time frame: 21 days

  4. Clearance at steady-state of ICT01

    PK parameter from serum ICT01 levels

    Time frame: 6 months

  5. Half-life of ICT01

    PK parameter from serum ICT01 levels

    Time frame: 6 months

  6. Objective Response Rate using RECIST for solid tumor patients (Part 2)

    RECIST is measured every 8 weeks during treatment

    Time frame: 12 months

07

Study locations

29 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2020 (actual). Primary completion is estimated for Oct 2027, 91 months after the start.

Of 64 phase 1/2 interventional studies under Hematologic Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 127. This study's planned 91 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2020
First posted
Jan 28, 2020
StartActual
Mar 5, 2020
Primary completionEst.
Oct 15, 2027
CompletionEst.
Oct 15, 2027
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04243499
Responsible party
Sponsor
First posted
Jan 28, 2020
Start date
Mar 5, 2020
Primary completion
Oct 15, 2027 (estimated)
Completion
Oct 15, 2027 (estimated)
Last update
Sep 4, 2026

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-BTN3A Agonistic Monoclonal Antibody ICT01

Start the discussion